Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jonker

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 21, 2013
Evaluation of an alternative in vitro test battery for detecting reproductive toxicantsA H Piersma, S Bosgra, M B M van Duursen, et al.
Cardiovascular and Interventional Radiology|January 9, 2023
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin TrialT M L Tong, M C Burgmans, F M Speetjens, et al.
The Oncologist|September 19, 2025
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinomaJorien B E Janssen, Kirti K Iyer, Sophie L Gerritse, et al.
Oncoimmunology|June 13, 2024
Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancerLotte Bakkerus, Beatriz Subtil, Hetty J Bontkes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alphaEls M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij, et al.
Database : the Journal of Biological Databases and Curation|August 8, 2024
The overview of the BioRED (Biomedical Relation Extraction Dataset) track at BioCreative VIIIRezarta Islamaj, Po-Ting Lai, Chih-Hsuan Wei, et al.
Clinical Genetics|May 16, 2017
The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriersJ A Rijken, N D Niemeijer, M A Jonker, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 21, 2013
Evaluation of an alternative in vitro test battery for detecting reproductive toxicantsA H Piersma, S Bosgra, M B M van Duursen, et al.
Cardiovascular and Interventional Radiology|January 9, 2023
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin TrialT M L Tong, M C Burgmans, F M Speetjens, et al.
The Oncologist|September 19, 2025
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinomaJorien B E Janssen, Kirti K Iyer, Sophie L Gerritse, et al.
Oncoimmunology|June 13, 2024
Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancerLotte Bakkerus, Beatriz Subtil, Hetty J Bontkes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alphaEls M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij, et al.
Database : the Journal of Biological Databases and Curation|August 8, 2024
The overview of the BioRED (Biomedical Relation Extraction Dataset) track at BioCreative VIIIRezarta Islamaj, Po-Ting Lai, Chih-Hsuan Wei, et al.
Clinical Genetics|May 16, 2017
The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriersJ A Rijken, N D Niemeijer, M A Jonker, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Pageof 20